<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03157102</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL17_0035</org_study_id>
    <secondary_id>IDRCB</secondary_id>
    <nct_id>NCT03157102</nct_id>
  </id_info>
  <brief_title>High Flow Nasal Cannula in Children With Status Asthmaticus</brief_title>
  <acronym>CANULASTHM</acronym>
  <official_title>High Flow Nasal Cannula Versus Standard Oxygen Therapy in Children With Status Asthmaticus: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In France, over 2.5 million people suffer from asthma, including one-third of children. This
      is the chronic respiratory disease leading to the highest rate of hospitalization. The
      conventional oxygen delivery means in children are the non-rebreather face mask or low flow
      nasal cannula (standard oxygen therapy - SOT). New non-invasive ventilatory support systems
      such as High Flow Nasal Cannula (HFNC) are emerging. These are nasal cannulas allowing the
      delivery of a high air (or oxygen) flow, exceeding the inspiratory flow of patients with
      acute respiratory failure, allowing to deliver a slight positive expiratory pressure while
      ensuring humidification and warming of the airways. Aerosol administration is also possible
      with excellent efficiency and without interrupting respiratory assistance. Physiological data
      and clinical studies in other pathologies suggest the interest of this technique during the
      asthma attack, but no comparative study currently exists in this indication. The HFNCs could
      have their place upstream of Non Invasive Ventilation (NIV), thus replacing non-rebreather
      face mask sometimes not tolerated by the children. The investigators's hypothesis is that
      HFNCs could improve patients' health faster, reduce the use of other ventilatory assistance
      (NIV, invasive ventilation) and reduce the duration of hospitalization in intensive care
      units or continuous monitoring units (CMU).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 8, 2018</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with first line treatment Failure as defined below in the first 24 hours</measure>
    <time_frame>up to hour 24</time_frame>
    <description>First line treatment Failure in the first 24 hours is defined as:
Occurrence or worsening of hypercapnic acidosis (pH&lt;7.35 with pCO2&gt;45 mmHg)
Or worsening of PRAM score (&gt;=2 from baseline)
Or SpO2&lt;92% with maximal flow of oxygen depending on age in the group standard oxygen therapy or with FiO2 &gt; 60% associated with a flow between 1 and 3L/Kg/min in the HFNC group
Or occurrence or worsening of the level of consciousness with Glasgow coma scale &lt; 12
Or the need of invasive or noninvasive ventilation (Glasgow coma scale&lt;8, hemodynamic instability, refractory hypoxemia) at any time during the first 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients requiring noninvasive ventilation (NIV)</measure>
    <time_frame>month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients requiring invasive ventilation (IV).</measure>
    <time_frame>month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of invasive ventilation (IV).</measure>
    <time_frame>month 1</time_frame>
    <description>Duration in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of noninvasive ventilation (NIV)</measure>
    <time_frame>month 1</time_frame>
    <description>Duration in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comfort assessed by the FLACC score</measure>
    <time_frame>up to hour 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of supplemental oxygen therapy (in hours)</measure>
    <time_frame>month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from inclusion to restoration of a PRAM score &lt; 8 (in hours).</measure>
    <time_frame>month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from inclusion to blood gas normalization (pCO2&lt;45 mmHg and pH&gt;7.35) if available (hours)</measure>
    <time_frame>month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative dose of treatments (salbutamol, corticosteroid magnesium sulfate)</measure>
    <time_frame>month 1</time_frame>
    <description>in milligram during PICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total number of hours of PICU stay</measure>
    <time_frame>month 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Status Asthmaticus</condition>
  <arm_group>
    <arm_group_label>HFNC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Oxygen Therapy group (STO group)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HFNC</intervention_name>
    <description>Oxygen therapy will be delivered through high flow nasal cannulas. Aerosol treatments will be administered through a vibrating mesh nebulizer directly connected to the circuit (aerogen®). The airvo® system (Fisher &amp; Peykel Healthcare, Auckland, New Zealand) will be used as the high flow cannula system in the study. Cannula size will be tailored to the child according to the manufacturer's recommendations. The gas flow will be adjusted according to the child's weight in a predefined chart. FiO2 will be adjusted to allow for a SpO2 &gt;92%.
All the patients, regardless of their treatment failure status, will be evaluated at H2, H6, H12 and H24 to monitor their evolution (evaluation of the standard parameters, consciousness, PRAM (Pediatric Respiratory Assessment Measure) score, pain assessment by the FLACC (Face Legs Activity Cry Consolability) score). .</description>
    <arm_group_label>HFNC group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard Oxygen Treatment</intervention_name>
    <description>Children will receive supplemental oxygen as commonly delivered through a non-rebreather face mask or low flow nasal cannula (standard oxygen treatment) and beta2 agonist aerosol via vibrating mesh nebulizer (aerogen®) according to the procedures usually used in the unit and according to the GINA (Global Initiative for Asthma) protocol. This group is the standard treatment group and is therefore the control group.
All the patients, regardless of their treatment failure status, will be evaluated at H2, H6, H12 and H24 to monitor their evolution (evaluation of the standard parameters, consciousness, PRAM score, pain assessment by the FLACC score). The use of adjuvant therapies (magnesium sulfate, salbutamol IVSE, and ipratropium bromide) will remain at the discretion of the physician in charge of the child and will be evaluated as a secondary criterion.</description>
    <arm_group_label>Standard Oxygen Therapy group (STO group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 6 months and &lt;18 years old

          -  Hospitalized in PICU with status asthmaticus defined by

               1. a PRAM score &gt; 7 with no response at H2 to the conventional treatment according
                  to the GINA (Global Initiative for Asthma guidelines) protocol: Oxygen therapy,
                  Continuous nebulization of beta2 agonist for at least one hour then every hour,
                  Oral or intravenous corticosteroid (ie methylprednisolone 2mg/kg/j)

               2. or with hypercapnic acidosis (pCO2 &gt; 45 mmHg and pH &lt; 7,35)

          -  Informed consent signed by at least on parent or legal guardians prior to inclusion
             and oral consent of the other parent if absent

        Exclusion Criteria:

          -  Non-corrected congenital heart disease, or neuromuscular disease, or chronic
             respiratory disease (pulmonary or bronchial fibrosis, cystic fibrosis), or ENA disease
             (laryngo or tracheo malacia), scoliosis or chronic metabolic disease

          -  Need for non-invasive or invasive ventilation (Glasgow comas scale &lt;8, hemodynamic
             instability, refractory hypoxemia, cardiac arrest)

          -  Pneumothorax confirmed on the X-ray

          -  No national health coverage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robin Pouyau, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robin Pouyau, Dr</last_name>
    <phone>472 129 747</phone>
    <phone_ext>+33</phone_ext>
    <email>robin.pouyau@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tiphanie Ginhoux</last_name>
    <phone>427 857 723</phone>
    <phone_ext>+33</phone_ext>
    <email>tiphanie.ginhoux@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Femme-Mère-Enfant</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin POUYAU, MD</last_name>
    </contact>
    <investigator>
      <last_name>Florent BAUDIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Wroblewski</last_name>
      <email>Iwroblewski@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Wroblewski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipe Durand</last_name>
    </contact>
    <investigator>
      <last_name>Philipe Durand</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Timone 2</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice Michel</last_name>
      <email>fabrice.michel@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Fabrice Michel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Annecy Genevois</name>
      <address>
        <city>Metz-Tessy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clémence Jarrasse</last_name>
      <email>cjarrasse@ch-annecygenevois.fr</email>
    </contact>
    <investigator>
      <last_name>Clémence Jarrasse</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Milési</last_name>
      <email>c-milesi@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe Milési</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Bourgoin</last_name>
    </contact>
    <investigator>
      <last_name>Pierre Bourgoin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Lenval</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mickael Afanetti</last_name>
    </contact>
    <investigator>
      <last_name>Mickael Afanetti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane Dauger</last_name>
      <email>stephane.dauger@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane Dauger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg,</name>
      <address>
        <city>Strasbourg,</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Sophie GUILBERT Anne-Sophie</last_name>
      <email>anne-sophie.guilbert@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Anne-Sophie GUILBERT Anne-Sophie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Villefranche sur Saône,</name>
      <address>
        <city>Villefranche sur Saône</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Tochon</last_name>
      <email>MTochon@lhopitalnordouest.fr</email>
    </contact>
    <investigator>
      <last_name>Marie Tochon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 2, 2017</study_first_submitted>
  <study_first_submitted_qc>May 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2017</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>children</keyword>
  <keyword>status asthmaticus</keyword>
  <keyword>HFNC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Status Asthmaticus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

